#United States #New York #Pomerantz LLP #Larimar Therapeutics #safety signals

Investor Alert: Investigating Larimar Therapeutics

The Pomerantz Law Firm is actively investigating allegations of potential securities fraud involving Larimar Therapeutics, Inc. (NASDAQ: LRMR), as concerns mount over the safety profiles reported in their clinical trials for a treatment aimed at Friedreich's Ataxia. This investigation aims to provide insight and assistance to investors who may have suffered losses as a result of these troubling developments.

Overview of the Company and Clinical Trials

Larimar Therapeutics has been working on the development of nomlabofusp, a treatment designed for individuals afflicted with Friedreich's Ataxia. This condition poses numerous challenges for patients, and Larimar’s commitment to developing novel therapies has positioned them as a key player in the biotech industry. However, the company faces scrutiny due to safety issues reported during ongoing clinical trials.

Recent Events and Effects on Stock Performance

On September 29, 2025, Larimar reported what it initially deemed "positive" data from its long-term open-label study involving daily subcutaneous injections of nomlabofusp. Despite this characterization, the press release revealed that anaphylaxis, a severe allergic reaction, was reported by seven participants in the study. Following this announcement, Larimar’s stock took a considerable hit, plunging $1.72 per share (33.66%) to close at $3.38.

Just a few months later, on June 29, 2026, Larimar released new study results confirming the submission of the first section of its rolling Biologics License Application seeking accelerated approval for nomlabofusp. Encouragingly, while the data released again aimed to convey a sense of positivity, it also noted that anaphylaxis occurred in 10 out of 43 patients in this trial. That announcement compelled investors to reassess their positions, yet again leading to a decrease in stock value by $0.46 per share (12.57%), closing at $3.20.

Pomerantz’s Role and Class Action Potential

In light of the significant impacts these disclosures seem to have on Larimar's stock prices, Pomerantz LLP has initiated an investigation into whether Larimar and certain officers and directors may have engaged in securities fraud or other unlawful business practices. The firm encourages investors who have suffered losses to reach out. This exploration could lead to a class-action lawsuit, providing affected investors with a collective chance to recover any financial losses sustained.

With a history of success in handling corporate, securities, and antitrust class litigation, Pomerantz has built a robust reputation over its 85 years of operations. The firm's dedication to fighting for the rights of victims across various sectors underscores its commitment to ensuring accountability in corporate governance. Those interested in more information can visit Pomerantz’s website.

Contact Information for Affected Investors

If you are an investor who has faced losses related to Larimar Therapeutics, you may contact Danielle Peyton at Pomerantz LLP via email at [email protected] or call 646-581-9980, ext. 7980, for assistance. Your participation in this investigation could help shed light on the events leading up to the stock's volatility and ensure that your rights are protected as an investor.

Conclusion

Investing in biotechnology firms such as Larimar Therapeutics can present both high rewards and significant risks, especially when developments in clinical trials reveal serious safety issues. The Pomerantz Law Firm believes it is imperative to investigate these matters thoroughly to protect investors and hold companies accountable for their actions. By addressing these concerns, the firm continues to uphold the principles of transparency and corporate responsibility, which are critical in the realm of investor relations.